Dsc Advisors adds Global Blood Therapeutics Inc (GBT) to its portfolio

Global Blood Therapeutics Inc (GBT) : Dsc Advisors added new position in Global Blood Therapeutics Inc during the most recent quarter end. The investment management firm now holds 65,000 shares of Global Blood Therapeutics Inc which is valued at $1,426,750 , the company said in a statement filed on Aug 15, 2016 with the SEC.Global Blood Therapeutics Inc makes up approximately 0.89% of Dsc Advisors’s portfolio.

Other Hedge Funds, Including , Manufacturers Life Insurance Company The boosted its stake in GBT in the latest quarter, The investment management firm added 3,904 additional shares and now holds a total of 5,096 shares of Global Blood Therapeutics Inc which is valued at $111,857.Tiaa Cref Investment Management boosted its stake in GBT in the latest quarter, The investment management firm added 22,748 additional shares and now holds a total of 44,761 shares of Global Blood Therapeutics Inc which is valued at $982,504.Tower Research Capital (trc) boosted its stake in GBT in the latest quarter, The investment management firm added 189 additional shares and now holds a total of 1,331 shares of Global Blood Therapeutics Inc which is valued at $29,215.Blackrock Investment Management boosted its stake in GBT in the latest quarter, The investment management firm added 46,486 additional shares and now holds a total of 70,327 shares of Global Blood Therapeutics Inc which is valued at $1,543,678.

On the company’s financial health, Global Blood Therapeutics Inc reported $-0.58 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Aug 10, 2016. Analyst had a consensus of $-0.63.During the same quarter in the previous year, the company posted $-4.84 EPS.

Global Blood Therapeutics Inc. is a biopharmaceutical company that engages in discovering developing and commercializing therapeutics to treat blood-based disorders. The Company is engaged in developing initial product candidate GBT440 oral prophylactic therapy for sickle cell disease (SCD). The Company offers randomized placebo-controlled double-blind single and multiple ascending dose Phase 1/2 clinical trial of GBT440 in healthy subjects and patients with SCD. It is also developing hemoglobin modifiers for pulmonary disorders such as acute respiratory distress syndrome in which increased oxygen delivery is needed. The Company through its GBT440 or analog also focuses on chemical and biological mechanisms of blood-based disorders to target hypoxemic pulmonary disorders and hereditary angioedema (HAE) which is in pre-clinical trials. In addition the Company develops TBD an oral kallikrein inhibitor which are in Phase 1/2 clinical trials.

Leave a Reply

Global Blood Therapeutics Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Global Blood Therapeutics Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.